MTOR and neoplasm: Hence, anti-PD1 treatment not only blocks inhibitory receptors but also can suppress tumor growth by directly regulating tumor cell metabolism via modulating mTOR activity and reducing the glucose exhaustion in TME, which promotes CD8+ cytotoxic T lymphocyte (CTL) functions, suggesting a very effective and promising advancement for therapies targeting both tumor immunity and TME.